OCR 5339 is a novel serum-based biomarker assay that determines disease severity and provides a prediction of the progression of scleroderma.
The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
Researchers at Yale have identified a specific HPV DNA methylation signature in cervical cells that may have prognostic value for cervical cancer.
8 genetic loci for intracranial aneurysm susceptibility have been identified. These common variants can be utilized in the development of cost-effective and easily applicable genetic screening tests. In particular, the genotype of the patients at a particular locus, such as EDNRA, can be used not only for risk prediction but also for treatment guidance, such as whether a patient is likely to respond to a specific medication.
Yale University investigators have developed a new MR imaging method that accelerates image acquisition beyond conventional and parallel imaging methods. Rather than using linear encoding gradients as employed by current parallel imaging methods, O-space imaging utilizes nonlinear fields as encoding gradients and eliminates phase encoding. Since the spatial encoding gradient shapes are tailored to an existing surface coil array, more efficient use is made of the spatial information in the coil profiles. As an added benefit, nonlinear gradients may be ramped faster than linear gradients, further reducing image acquisition times.
Proteomic analysis of cord blood samples obtained at birth has identified biomarkers that correlate with the development of Early Onset Neonatal Sepsis (EONS) and with an adverse neonatal outcome that is independent of gestational age at birth and birth weight. These protein markers represent the basis for a diagnostic test that could easily be automated. Cord blood sampling is used to monitor cord blood gases at delivery so sampling for this assay would be routine. Such an assay would provide the physician with a rapid and accurate assessment of the risk of EONS in newborns.
In a collaborative study, Yale researchers have developed a novel DNA-based diagnostic that detects mutations in ion channels in patients presenting with hypertension due to primary aldosteronism (PA). Somatic mutations cause increased sodium ion conductance, cell depolarization, and intracellular calcium levels have been revealed in 47% of sporadically occurring aldosterone-producing adenomas. This test may eliminate the requirement for the conventional, yet invasive, adrenal vein sampling, thereby streamlining the diagnostic evaluation of severe hypertension. Furthermore, this technology can indicate a direct diagnosis for a surgically correctable form of the disease, in which an adrenalectomy can cure hypertension and correct hypokalemia in the large majority of patients with increased aldosterone due to PA. Most importantly, this genetic test can be used as a stand-alone or a companion diagnostic in all patients with worsening or difficult-to-treat hypertension leading to markedly improved care and reduced overall costs. In addition to this, antibody therapy could be developed to inhibit or decrease the mutated potassium channel activity, and thereby present a new therapeutic option for treatment of this patient group
Researchers at Yale University have developed a unique PCR-based fecal diagnostic test that can predict the onset of inflammatory bowel disease (IBD).